KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
KEYTRUDA® (pembrolizumab), as monotherapy, is indicated for the treatment of adult and adolescent (12 years and older) patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).